Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study - Université de Lorraine Access content directly
Journal Articles World Journal of Gastroenterology Year : 2022

Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study

Talat Bessissow
  • Function : Author
Geoffrey Nguyen
  • Function : Author
Osman Tarabain
  • Function : Author
Nathalie Foucault
  • Function : Author
Kevin Mchugh
  • Function : Author
Joannie Ruel
  • Function : Author

Abstract

A gap remains in documenting the impact of anti-tumor necrosis factor therapy on disease burden in ulcerative colitis (UC) patients treated in a real-world setting. The use of patient-reported outcomes (PROs) has been discussed as a primary endpoint in the context of the FDA PRO Guidance, for labelling purposes. Specifically, the efficacy and safety of adalimumab have been demonstrated in pivotal trials; however, data are needed to understand how clinical results translate into improvements in key aspects of the daily lives of UC patients, such as symptoms, health-related quality of life (HRQoL), and disability.

Dates and versions

hal-04168330 , version 1 (21-07-2023)

Identifiers

Cite

Talat Bessissow, Geoffrey Nguyen, Osman Tarabain, Laurent Peyrin-Biroulet, Nathalie Foucault, et al.. Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study. World Journal of Gastroenterology, 2022, 28 (34), pp.5058-5075. ⟨10.3748/wjg.v28.i34.5058⟩. ⟨hal-04168330⟩

Collections

UNIV-LORRAINE
1 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More